替奈普酶在中重度缺血性卒中患者中的安全性与结局
NOR-TEST 试验的事后分析评估替奈普酶 0.4 mg/kg 与阿替普酶 0.9 mg/kg 在中重度缺血性卒中患者中的安全性和疗效。中度卒中患者两药在良好结局、症状性颅内出血和死亡率上无差异;重度卒中患者 90 天全因死亡率在替奈普酶组升高。
要点
- 中度卒中患者替奈普酶与阿替普酶的安全性及结局相似。
- 重度卒中患者替奈普酶组 90 天全因死亡率高于阿替普酶组。
- 重度卒中患者使用替奈普酶 0.4 mg/kg 需密切监测安全性指标。
核心结论
- 在中度和重度缺血性卒中患者中,替奈普酶与阿替普酶的良好结局率和症状性颅内出血率相似。
- 重度卒中患者接受替奈普酶后 90 天死亡率增加。
研究设计与样本
- NOR-TEST 为 III 期试验,比较替奈普酶 0.4 mg/kg 与阿替普酶 0.9 mg/kg 在缺血性卒中中的安全性和疗效。
- 本分析为事后分析,中度卒中定义为入院 NIHSS 6 至 14 分,重度卒中定义为 NIHSS≥15 分。
- 中度卒中患者 n=261,重度卒中患者 n=87。
主要发现
- 中度卒中患者中,替奈普酶与阿替普酶在良好结局、症状性颅内出血和死亡率方面无差异。
- 重度卒中患者中,两组在结局、症状性颅内出血频率和 7 天死亡率方面无差异。
- 重度卒中患者 90 天全因死亡率在替奈普酶组升高(10 例[26.3%]对 4 例[9.1%];P=0.045)。
- 替奈普酶组 1 例死于症状性颅内出血,阿替普酶组 2 例死于症状性颅内出血。
关键数值与推荐
- 中度卒中:入院 NIHSS 6 至 14 分;重度卒中:入院 NIHSS≥15 分。
- 替奈普酶剂量 0.4 mg/kg,阿替普酶剂量 0.9 mg/kg。
- 重度卒中 90 天全因死亡率:替奈普酶组 10 例(26.3%)对阿替普酶组 4 例(9.1%),P=0.045。
临床怎么用
- 中度缺血性卒中患者可考虑替奈普酶 0.4 mg/kg 作为阿替普酶的替代。
- 重度卒中患者使用替奈普酶 0.4 mg/kg 时应密切监测安全性,尤其关注 90 天死亡率。
局限性
- 本研究为 NOR-TEST 的事后分析,重度卒中亚组样本量较小(n=87)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Tenecteplase represents a promising alternative to alteplase as thrombolytic treatment in acute ischemic stroke. There are limited data on tenecteplase 0.4 mg/kg in patients with increased stroke severity. We aimed to assess safety and efficacy of tenecteplase 0.4 mg/kg in patients with moderate and severe ischemic stroke. Methods- NOR-TEST (Norwegian Tenecteplase Stroke Trial) was a phase III trial designed to investigate the safety and efficacy of tenecteplase 0.4 mg/kg versus alteplase 0.9 mg/kg in ischemic stroke. In this post hoc analysis, moderate stroke was defined as admission National Institutes of Health Stroke Scale; 6 to 14 and severe stroke as National Institutes of Health Stroke Scale; ≥15. Rates of favorable outcome at 90 days, symptomatic intracerebral hemorrhage (sICH), and mortality after 7 and 90 days were assessed. Results- In patients with moderate stroke (n=261), there were no differences in rates of favorable outcome, sICH, or mortality between tenecteplase and alteplase. In patients with severe stroke (n=87), there were no differences in outcome, frequency of sICH, or mortality at 7 days, but all-cause mortality at 90 days was increased in patients treated with tenecteplase (10 [26.3%] versus 4 [9.1%]; P=0.045). One patient died of sICH in the tenecteplase group, and 2 patients died of sICH in the alteplase group. Conclusions- Rates of favorable outcome and sICH were similar between treatment groups in patients with moderate and severe stroke. Mortality after 90 days was increased in patients with severe stroke receiving tenecteplase. Future studies assessing tenecteplase 0.4 mg/kg should monitor safety parameters closely in patients with severe stroke. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01949948.
引用
- Kvistad CE, Novotny V, Kurz MW, et al. Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke. Stroke. 2019. PMID: 31009339. doi:10.1161/STROKEAHA.119.025041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。